RCEL (44) SENS (38) SGHT (38) DCTH (57) ⌘ Pro Terminal →

AngioDynamics Inc. (ANGO) — RQD Stock Rating Cockpit

$12.35 +1.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

AngioDynamics Inc. (ANGO) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $519.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANGO)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

39.430 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.12>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE43% OF RANGE

L: $9$12.35H: $16

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ANGO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

-23.4% ROIC with 54.6% gross margin and 0.10% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 2.12 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

17/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like ANGO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANGO)

✓Walkthrough of ANGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.89%📐 HORIZONTAL RANGE

2026-10-30O $12.32H $12.35L $11.89C $12.35VOL 475.8K

RES: $17.68SUP: $10.46SMA50: $14.18SMA200: $12.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANGO Butterfly Map → + Track ANGO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +9.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANGO)

Health Care Rank #344 of 1016 ⚔️ RCEL vs ANGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANGO vs. RCEL, SENS, SGHT, DCTH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AngioDynamics Inc. (ANGO) ranks #344 by composite RQD confidence (50/100, grade D) and #441 by equity capitalization ($519.4M). Within this direct 5-issuer industry benchmark cohort, ANGO leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with ANGO at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANGO ACTIVE AngioDynamics Inc.	D	50/100	—	54.6%	-23.4%	+1.81%	$519.4M	Benchmark Subject
RCEL Avita Medical Inc.	D	44/100	—	82.1%	-35.0%	+1.27%	$516.8M	/rcel-vs-ango →
SENS Senseonics Holdings Inc.	D-	38/100	—	44.7%	-35.0%	+4.39%	$515.5M	/sens-vs-ango →
SGHT Sight Sciences Inc.	D-	38/100	—	86.2%	-35.0%	+3.57%	$527.2M	/sght-vs-ango →
DCTH Delcath Systems Inc.	D+	57/100	—	86.2%	0.8%	-1.48%	$508.0M	/dcth-vs-ango →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001275187

In its most recent audited fiscal period (FY2025, filed 2026-05-31), AngioDynamics Inc. (ANGO) reported GAAP revenue of $320.2M (+9.5% vs. FY2024 revenue of $292.5M , and +5.4% cumulative change since FY2023) , GAAP net income of -$36.7M, operating cash flow of $3.1M, and free cash flow of $508.0K (+103.5% YoY). On the balance sheet, ANGO closed FY2025 with $269.7M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$320.2M	-$36.7M	$3.1M	$508.0K	$269.7M	—
FY2024 (FY)	2025-05-31	$292.5M	-$34.0M	-$10.1M	-$14.6M	$291.6M	—
FY2023 (FY)	2024-05-31	$303.9M	-$184.3M	-$28.2M	-$28.2M	—	—

3. ANGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AngioDynamics Inc. (NASDAQ: ANGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $12.35 (+1.81% 1D, market cap $519.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANGO ranks #344 in composite RQD confidence.

How does ANGO compare to RCEL and SENS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M) and SENS (Senseonics Holdings Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M). Among the 5-stock peer group, ANGO leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANGO?

Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ANGO last traded at $12.35 (+1.81% on volume of 476,210 shares), positioning the stock -12.91% below its 50-day simple moving average ($14.18) and -1.04% below its 200-day simple moving average ($12.48). Across its 52-week range of $9.39 to $16.29, ANGO sits at the 42.9% percentile with a 14-day RSI of 39.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.81 to $13.89).

ANGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ANGO stock right now?

AngioDynamics Inc. (ANGO) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.

What is ANGO's 12-month price target and RQD AI Jury consensus?

ANGO's 12-month base price target is $11.91 (range $9.29 to $17.1), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ANGO RQD Cockpit ANGO 12M Forecast ANGO Earnings & Move ANGO Dividends & DRIP ANGO Insiders & 13F ANGO Whale Options ANGO Profit Sankey ANGO News & Why